Marc Fatar

TL;DR: Although IMT has been suggested to represent an important risk marker, according to the current evidence it does not fulfill the characteristics of an accepted risk factor and will help to improve the power of randomized clinical trials incorporating IMT measurements and to facilitate the merging of large databases for meta-analyses.

TL;DR: The consensus concludes that there is no need to ‘treat IMT values’ nor to monitor IMTvalues in individual patients apart from few exceptions and that IMT does not fulfill the characteristics of an accepted risk factor.

TL;DR: Patients with ischaemic stroke 4·5-9 h from stroke onset or wake-up stroke with salvageable brain tissue who were treated with alteplase achieved better functional outcomes than did patients given placebo, and this increase in the rate of symptomatic intracerebral haemorrhage did not negate the overall net benefit of thrombolysis.

TL;DR: The data confirm the concept of cancer-associated hypercoagulation as a widely underestimated important stroke risk factor in patients with cancer, especially in those with severely elevated D-dimer levels and in the absence of conventional risk factors.

TL;DR: Abciximab immunobubbles improve visualization of human clots both in vitro and in an in vivo model of acute arterial thrombotic occlusion, demonstrating the feasibility of using a therapeutic agent for selective targeting in vascular imaging.